Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Follistatin vs Follistatin 344

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 344 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 344 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Follistatin

Preclinical + Gene Therapy Trials

Follistatin 344

Preclinical

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Follistatin Follistatin 344
Class Myostatin-binding glycoprotein; anabolic Follistatin isoform; anabolic
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds and neutralizes myostatin and activin; promotes muscle growth Tissue-bound follistatin precursor; local myostatin inhibition
Route SC injection SC injection
Half-life Variable by isoform ~hours
Dosage (research) 100-500 mcg SC daily (research) 100-500 mcg SC daily
Evidence tier Preclinical + Gene Therapy Trials Preclinical
Research depth 218 indexed (PubMed 170 · CT 3 · EPMC 45) 25 indexed (PubMed 10 · CT 0 · EPMC 15)
Availability Research Chemical Research Chemical
Reported risks Activin off-target effects; fertility concerns; limited human data Same as Follistatin; limited data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Follistatin or Follistatin 344?

Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 344 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 344 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Follistatin and Follistatin 344?

Follistatin is classed as Myostatin-binding glycoprotein; anabolic; Follistatin 344 is classed as Follistatin isoform; anabolic. Reported mechanism: Follistatin, Binds and neutralizes myostatin and activin; promotes muscle growth; Follistatin 344, Tissue-bound follistatin precursor; local myostatin inhibition. Reported half-life: Follistatin, Variable by isoform; Follistatin 344, ~hours. Routes in published studies: Follistatin, SC injection; Follistatin 344, SC injection.

Which has stronger evidence, Follistatin or Follistatin 344?

Follistatin and Follistatin 344 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Follistatin is graded Preclinical + Gene Therapy Trials, with 20 cited sources on its reference page and 218 indexed studies. Follistatin 344 is graded Preclinical, with 2 cited sources on its reference page and 25 indexed studies.

Which is more accessible, Follistatin or Follistatin 344?

Neither Follistatin nor Follistatin 344 is an FDA-approved drug. Catalog status: Follistatin, Research Chemical; Follistatin 344, Research Chemical.

Are Follistatin and Follistatin 344 ever combined?

Follistatin and Follistatin 344 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…